Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.

Breast cancer research and treatment - 1 Nov 2018

Barnes-Kedar Inbal, Bernstein-Molho Rinat, Ginzach Nava, Hartmajer Shulamit, Shapira Tamar, Magal Nurit, Kalis Marina Lifshitc, Peretz Tamar, Shohat Mordechai, Basel-Salmon Lina, Friedman Eitan, Bazak Lily, Goldberg Yael

Abstract excerpt

PURPOSE: BRCA1 and BRCA2 genotyping results have clinical implications for cancer risk assessment and targeted therapy. Current practice in Israel is to genotype for the predominant BRCA1/2 mutations first, followed by full gene analysis in eligible mutation-negative individuals. This work assessed the rate of non-predominant mutations in BRCA1/2 in ethnically diverse high-risk cases. METHODS: Breast and/or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Germ-Line Mutation
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Israel

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 30014164
DOI: 10.1007/s10549-018-4887-7

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.PMID 30014164Read ↗

The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.Semantic proximity Read ↗

Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.Semantic proximity Read ↗

[GENOTYPE-PHENOTYPE CORRELATIONS BY SPECIFIC FOUNDER VARIANTS IN BRCA IN ISRAELI WOMEN].Semantic proximity Read ↗

Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.Semantic proximity Read ↗

BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.Semantic proximity Read ↗

Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel.Semantic proximity Read ↗

Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.Semantic proximity Read ↗

Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.Semantic proximity Read ↗

Characterization of BRCA1 and BRCA2 mutations in a large United States sample.Semantic proximity Read ↗

Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.Semantic proximity Read ↗

Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel.Semantic proximity Read ↗

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.